A Randomized, Placebo-Controlled, Double-Blind Pilot Study of Pioglitazone Hydrochloride in Severe, Refractory Asthma

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

15 participants

Study Classification

INTERVENTIONAL

Study Start Date

2009-09-23

Study Completion Date

2016-06-24

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Background:

\- Individuals who have severe asthma that is not easily controlled by current treatments are in need of new treatments to prevent potentially life-threatening asthma attacks. Experiments in mice have found that a medication called pioglitazone hydrochloride (Actos ), which is used to treat patients with diabetes, may be effective for treating severe asthma. Researchers are interested in determining whether Actos is effective in improving the quality of life in subjects with severe asthma who continue to have symptoms despite maximum standard medical therapy.

Objectives:

\- To assess the effectiveness of pioglitazone hydrochloride as a treatment for patients with severe asthma that is not controlled by standard treatments.

Eligibility:

\- Individuals between 18 and 75 years of age who have been diagnosed with and treated for severe asthma for at least 1 year.

Design:

* Potential participants will have a screening visit to determine eligibility for the study. The visit will involve breathing tests, chest x rays, heart and lung monitoring, and blood tests.
* Eligible participants will have a full medical history and will answer a series of questionnaires about their quality of life with asthma.
* Phase 1: Patients will record lung function and asthma symptoms morning and evening for 4 weeks. At the end of this period, patients will be evaluated with breathing, allergy, and blood tests, as well as questionnaires. Patients will also provide a sputum sample.
* Phase 2: Patients will receive regular doses of either pioglitazone hydrochloride or a placebo for 16 weeks. Patients will return to the National Institutes of Health every 4 weeks for tests.
* Phase 3: Wash-out period without study drugs for 4 weeks, similar to Phase 1.
* Phase 4: Patients will receive regular doses of either pioglitazone hydrochloride or a placebo for 16 weeks. Patients who received placebo will be given the study drug, and vice versa. Patients will return to the National Institutes of Health every 4 weeks for tests.
* Phase 5: Medications will be stopped, and patients will return to the National Institutes of Health 4 weeks later for final tests.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Pioglitazone Hydrochloride (Actos(Registered Trademark)) to Treat Asthma

NCT00604578

Asthma Airway Inflammation Airflow Obstruction +1 more

WITHDRAWN PHASE2

Pilot Study of Pioglitazone for the Treatment of Moderate to Severe Asthma in Obese Asthmatics

NCT00634036

Asthma

COMPLETED PHASE2

Repeated High-dose Inhaled Corticosteroids for Asthma

NCT00695604

Asthma

WITHDRAWN PHASE2

PF-04191834 Single Dose Bronchodilatory Study In Asthma.

NCT00723021

Asthma

COMPLETED PHASE2

A Safety and Efficacy Study of Inhaled R940343 in Patients With Mild to Moderate Asthma

NCT01591044

Asthma

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

New therapies are needed for patients with asthma who are sub-optimally controlled by standard measures. Pioglitazone hydrochloride (Actos ) is a highly selective and potent agonist for the peroxisome proliferator-activated receptor-Gamma (PPAR Gamma). Studies in murine models of allergic asthma have shown that PPAR Gamma agonists down-regulate allergen-mediated airway inflammation and airway hyperresponsiveness. This protocol is a randomized, placebo-controlled, doubleblind, crossover (phase II) pilot study of the efficacy of pioglitazone for the treatment of patients with severe, refractory asthma. The primary end-point for this study will be quality of life as determined by the Asthma Quality of Life Questionnaire (AQLQ) score. Secondary end-points will include indices of airway inflammation, airflow obstruction, airway hyperreactivity, and asthma symptoms.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Severe, Refractory Asthma Airway Inflammation Airflow Obstruction

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Pioglitazone, Then Placebo

Pioglitazone, 30 mg daily, was administered for the initial 2 weeks of the first treatment phase, followed by 45 mg daily for an additional 14 weeks. This was followed by a 4-week washout period. Subjects were assessed for clinical stability during a second 4-week run-in period prior to crossing over to the placebo phase for 16 weeks in the second treatment phase to receive the placebo.

Group Type EXPERIMENTAL

Pioglitazone

Intervention Type DRUG

Placebo

Intervention Type DRUG

Placebo, Then Pioglitazone

Placebo was administered for 16 weeks. This was followed by a 4-week washout period. Subjects were assessed for clinical stability during a second 4-week run-in period prior to crossing over to the Pioglitazone treatment group. Pioglitazone, 30 mg daily, was administered for the initial 2 weeks of the treatment phase, followed by 45 mg daily for an additional 14 weeks.

Group Type EXPERIMENTAL

Pioglitazone

Intervention Type DRUG

Placebo

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Pioglitazone

Intervention Type DRUG

Placebo

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Subjects will be between 18 and 75 years of age, male or female, with a diagnosis of severe, refractory asthma, as defined by the American Thoracic Society, for at least one year.
* Subjects must have a history of reversible airflow obstruction as defined by a positive methacholine bronchoprovocation challenge or a positive response to inhaled bronchodilators at some point in the course of their disease or a greater than 20% variability in the Forced Expiratory Volume in 1 second (FEV1) or the peak expiratory flow (PEF) documented during serial measurements of lung function over time.
* Left ventricular ejection fraction greater than or equal to 50% by echocardiogram
* For women of childbearing potential, negative pregnancy test prior to study and willingness to adhere to reliable birth control methods during the study.
* Subjects must have the ability to provide informed consent

Exclusion Criteria

* A known history of hypersensitivity to pioglitazone.
* Asthma exacerbation requiring treatment with additional oral corticosteroids in the previous 6 weeks, or a life-threatening asthma attack requiring cardiopulmonary support in the previous 6 months.
* Cigarette smoking within the previous 12 months or a prior history of \> 20 cumulative pack-years.
* Investigational therapy for any indication within I month prior to the screening visit.
* History of lung disease other than asthma (ie., COPD, sarcoidosis).
* History of diabetes mellitus requiring treatment with any medication, insulin secreting tumor, or symptomatic hypoglycemia.
* HIV/AIDS
* History of congestive heart failure with current symptoms consistent with NYHA classification II, Ill or IV.
* Preexisting edema (2+ or greater).
* Hemoglobin \< 11 gm/dl for males and \< 10 gm/dl for females.
* Active liver disease or abnormal liver function tests \> 2 times upper limit of normal.
* History of bladder or colon cancer.
* History of other cancer not in remission.
* Active breast feeding.
* Use of the following medications, which can interact with pioglitazone:

* Gemfibrizol (Lopid)
* Atazanivir (Reyataz)
* Ritonavir (Norvir)
* Rifampin (Rifadpin)
* Carbamzepine (Tegretol)
* Phenobarbital (Luminal)
* Phenytoin (Dilantin)
* Rifapentine (Priftin)
* Secobarbital (Seconal)
* Amiodarone (Cordarone, Pacerone)
* Palitaxel (Taxol)
* Replaglinide (Prandine)
* Ketoconazole (Nizoral)
* Atorvastatin (Lipitor )
* Fosphenytoin (Cerebyx)
* Itraconazole (Sporanox)
* Trimethoprim (in Bactrim)
* Thioridazine
* Certain over-the-counter herbs and supplements. These will be reviewed by the investigators for possible interactions with the study medication A determination of whether the supplement is safe to use with pioglitazone will be made on a case-by-case basis.
* Any condition that, in the investigator s opinion, places the patient at undue risk for complications from pioglitazone therapy.

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No